Euclises Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 11

Euclises General Information

Description

Developer of small-molecule immunometabolic drug candidates intended for use in oncology and inflammatory diseases. The company's platform focuses on developing novel inhibitors for use in the oncology setting, as well as creating a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary platform, enabling physicians to access advanced new molecules in combinations with both immune checkpoint and EGFR inhibitors to treat cancer.

Contact Information

Formerly Known As
Talley NewCo
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • BioGenerator Accelerator Labs
  • 4340 Duncan Avenue, Suite 240
  • Saint Louis, MO 63110
  • United States
+1 (314)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • BioGenerator Accelerator Labs
  • 4340 Duncan Avenue, Suite 240
  • Saint Louis, MO 63110
  • United States
+1 (314)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Euclises Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC Completed Generating Revenue
6. Secondary Transaction - Private 01-Aug-2020 Completed Generating Revenue
5. Later Stage VC 24-Apr-2018 Completed Generating Revenue
4. Early Stage VC (Series A) 06-Jan-2017 Completed Generating Revenue
3. Early Stage VC (Series A) 07-Apr-2015 Completed Generating Revenue
2. Early Stage VC 01-Jan-2015 $600K $775K Completed Generating Revenue
1. Early Stage VC 16-May-2012 $175K $175K Completed Generating Revenue
To view Euclises’s complete valuation and funding history, request access »

Euclises Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Euclises’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Euclises Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule immunometabolic drug candidates intended for use in oncology and inflammatory diseases. The
Drug Discovery
Saint Louis, MO
2 As of 2026

Basking Ridge, NJ
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Euclises Competitors (12)

One of Euclises’s 12 competitors is Lisata Therapeutics, a Corporation company based in Basking Ridge, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lisata Therapeutics Corporation Basking Ridge, NJ
AnTolRx Formerly VC-backed Cambridge, MA
Altimmune Formerly VC-backed Gaithersburg, MD
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Adastra Pharmaceuticals Formerly VC-backed San Mateo, CA
You’re viewing 5 of 12 competitors. Get the full list »

Euclises Patents

Euclises Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017206108-A1 Combination of a chromene compound and a second active agent Active 08-Jan-2016
AU-2017206108-B2 Combination of a chromene compound and a second active agent Active 08-Jan-2016
CA-3010848-A1 Combination of a chromene compound and a second active agent Active 08-Jan-2016
EP-3400218-A1 Combination of a chromene compound and a second active agent Inactive 08-Jan-2016
EP-3400218-A4 Combination of a chromene compound and a second active agent Inactive 08-Jan-2016 A61K31/352
To view Euclises’s complete patent history, request access »

Euclises Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Euclises Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Argonautic Ventures Venture Capital Minority
iSelect Fund Venture Capital Minority
Lagomaj Capital Venture Capital Minority
ABC Laboratories PE-Backed Company Minority
BioGenerator Ventures Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Euclises FAQs

  • When was Euclises founded?

    Euclises was founded in 2011.

  • Where is Euclises headquartered?

    Euclises is headquartered in Saint Louis, MO.

  • What is the size of Euclises?

    Euclises has 2 total employees.

  • What industry is Euclises in?

    Euclises’s primary industry is Drug Discovery.

  • Is Euclises a private or public company?

    Euclises is a Private company.

  • What is Euclises’s current revenue?

    The current revenue for Euclises is .

  • How much funding has Euclises raised over time?

    Euclises has raised $7.38M.

  • Who are Euclises’s investors?

    Argonautic Ventures, iSelect Fund, Lagomaj Capital, ABC Laboratories, and BioGenerator Ventures are 5 of 11 investors who have invested in Euclises.

  • Who are Euclises’s competitors?

    Lisata Therapeutics, AnTolRx, Altimmune, Inovio Pharmaceuticals, and Adastra Pharmaceuticals are some of the 12 competitors of Euclises.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process